B Singh1, F Powrie, N J Mortensen. 1. Nuffield Department of Surgery, John Radcliffe Hospital, Oxford, UK. baljit.singh@nds.ox.ac.uk
Abstract
BACKGROUND: A proliferation of animal models has not only improved our understanding of inflammatory bowel disease, it has also formed the basis of new treatment strategies. METHODS: A search was conducted using the National Library of Medicine for articles discussing immune therapies for inflammatory bowel disease. This was supplemented by findings from the authors' own laboratory. RESULTS: An overview of the different animal models is presented. These models are used to highlight the recent human trials of immune therapies. Potential future therapies are also discussed. CONCLUSION: Immune therapies have altered the management of patients with inflammatory bowel disease. In future they will influence not only the indications for surgery but also its timing and outcome.
BACKGROUND: A proliferation of animal models has not only improved our understanding of inflammatory bowel disease, it has also formed the basis of new treatment strategies. METHODS: A search was conducted using the National Library of Medicine for articles discussing immune therapies for inflammatory bowel disease. This was supplemented by findings from the authors' own laboratory. RESULTS: An overview of the different animal models is presented. These models are used to highlight the recent human trials of immune therapies. Potential future therapies are also discussed. CONCLUSION: Immune therapies have altered the management of patients with inflammatory bowel disease. In future they will influence not only the indications for surgery but also its timing and outcome.
Authors: Karol Sestak; Christopher K Merritt; Juan Borda; Elizabeth Saylor; Shelle R Schwamberger; Frank Cogswell; Elizabeth S Didier; Peter J Didier; Gail Plauche; Rudolf P Bohm; Pyone P Aye; Pavel Alexa; Richard L Ward; Andrew A Lackner Journal: Infect Immun Date: 2003-07 Impact factor: 3.441